103 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
or licensed) or the nature or conduct of its business makes such qualification necessary, except for those failures to be so qualified or in good … contribute to the aggregate losses, claims, damages, liabilities and expenses of the nature contemplated by such indemnification provision (including any
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
purchase and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those securities, or the method
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts;
whether the purchase
S-3ASR
qm8j55i3 oz7w
2 Jan 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.3
j1iyu2g m03g
2 Jan 24
Automatic shelf registration
4:06pm
D
4oecvli1u5mzxba9
4 Oct 23
$59.99 mm in equity / options / securities to be acquired, sold $59.99 mm, 14 investors
10:36am
8-K
EX-1.2
ofzyh1n694idcth
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
aaz0 e1tpa2
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
rayj8ol3uxep 4k3z
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
ixtj13ammmjeurmp
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
nrxxel 1g
27 Sep 23
Prospectus supplement for primary offering
5:26pm